Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lapatinib:

Lapatinib. Voigtlaender M et al. Recent Results Cancer Res. (2018)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. Eustace AJ et al. BMC Cancer. (2018)

Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions. Li Q et al. Am J Health Syst Pharm. (2016)

Search results

Items: 1 to 20 of 2615

1.

Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models.

Ando K, Wada T, Cao X.

Sci Rep. 2020 Jan 20;10(1):738. doi: 10.1038/s41598-020-57601-x.

2.

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Adamo B, Martínez O, Pernas S, López R, Muñoz M, Chic N, Galván P, Garau I, Manso L, Alarcón J, Martínez E, Gregorio S, Gomis RR, Villagrasa P, Cortés J, Ciruelos E, Prat A.

Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3.

PMID:
31959756
3.

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report.

Huang LT, Ma JT, Zhang SL, Li XH, Sun L, Jing W, Zhao JZ, Wang YR, Han CB.

Front Oncol. 2019 Dec 20;9:1453. doi: 10.3389/fonc.2019.01453. eCollection 2019.

4.

A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer.

Akbar MW, Isbilen M, Belder N, Canli SD, Kucukkaraduman B, Turk C, Sahin O, Gure AO.

J Cancer. 2020 Jan 1;11(4):949-961. doi: 10.7150/jca.34649. eCollection 2020.

5.

Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S.

J Carcinog. 2019 Dec 31;18:5. doi: 10.4103/jcar.JCar_14_19. eCollection 2019. Review.

6.

Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines.

Wan Mohamad Zain WNIZ, Bowen J, Bateman E, Keefe D.

Biomedicines. 2019 Dec 30;8(1). pii: E2. doi: 10.3390/biomedicines8010002.

7.

Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer.

Ding X, Tong C, Chen R, Wang X, Gao D, Zhu L.

J Mol Graph Model. 2019 Dec 26;96:107526. doi: 10.1016/j.jmgm.2019.107526. [Epub ahead of print]

PMID:
31901678
8.

ERRα activates SHMT2 transcription to enhance the resistance of breast cancer to lapatinib via modulating the mitochondrial metabolic adaption.

Li X, Zhang K, Hu Y, Luo N.

Biosci Rep. 2020 Jan 31;40(1). pii: BSR20192465. doi: 10.1042/BSR20192465.

PMID:
31894856
9.

Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine.

Modi ND, Sorich MJ, Rowland A, McKinnon RA, Koczwara B, Wiese MD, Hopkins AM.

Clin Breast Cancer. 2019 Dec 7. pii: S1526-8209(19)30715-3. doi: 10.1016/j.clbc.2019.10.001. [Epub ahead of print]

PMID:
31892489
10.

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.

Dratkiewicz E, Simiczyjew A, Pietraszek-Gremplewicz K, Mazurkiewicz J, Nowak D.

Int J Mol Sci. 2019 Dec 23;21(1). pii: E113. doi: 10.3390/ijms21010113.

11.

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).

Risi E, Biagioni C, Benelli M, Migliaccio I, McCartney A, Bonechi M, Guarducci C, Hilbers F, Di Cosimo S, Huober J, Romagnoli D, Boccalini G, Vitale S, Sotiriou C, Biganzoli L, Di Leo A, Malorni L.

Ther Adv Med Oncol. 2019 Dec 11;11:1758835919891608. doi: 10.1177/1758835919891608. eCollection 2019.

12.

Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma.

Fisher C, Obaid G, Niu C, Foltz W, Goldstein A, Hasan T, Lilge L.

J Clin Med. 2019 Dec 14;8(12). pii: E2214. doi: 10.3390/jcm8122214.

13.

Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.

Wang M, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Ferreira RB, Chiang CW, Guryanova OA, Kopinke D, Heldermon CD, Castellano RK, Law BK.

Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019.

14.

Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.

Bello M, Guadarrama-García C, Rodriguez-Fonseca RA.

J Comput Aided Mol Des. 2019 Dec 11. doi: 10.1007/s10822-019-00270-4. [Epub ahead of print]

PMID:
31828486
15.

CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.

Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, Del Genio C, Canfield K, DiRenzo J, Wells W, Gaur A, Robey RB, Guo JY, Powles RL, Sotiriou C, Pusztai L, Febbraio M, Cheng C, Kinlaw WB, Kurokawa M.

Cell Rep. 2019 Dec 10;29(11):3405-3420.e5. doi: 10.1016/j.celrep.2019.11.008.

16.

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.

Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G.

Breast. 2019 Nov 26;49:141-148. doi: 10.1016/j.breast.2019.11.012. [Epub ahead of print]

17.

Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's disease.

Nordmann TM, Messerli-Odermatt O, Meier L, Micaletto S, Coppetti T, Nägeli M, Kamarachev J, Kudura K, Freiberger SN, Rordorf T, Mangana J, Braun R, Dummer R.

Oncotarget. 2019 Nov 19;10(62):6647-6650. doi: 10.18632/oncotarget.27272. eCollection 2019 Nov 19.

18.

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.

Hassan MS, Williams F, Awasthi N, Schwarz MA, Schwarz RE, Li J, von Holzen U.

Sci Rep. 2019 Nov 26;9(1):17608. doi: 10.1038/s41598-019-54129-7.

19.

Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.

Ríos-Luci C, Díaz-Rodríguez E, Gandullo-Sánchez L, Díaz-Gil L, Ocaña A, Pandiella A.

Cancer Lett. 2020 Feb 1;470:161-169. doi: 10.1016/j.canlet.2019.11.026. Epub 2019 Nov 22.

PMID:
31765734
20.

Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.

Vacher L, Thivat E, Poirier C, Mouret-Reynier MA, Chollet P, Devaud H, Dubray-Longeras P, Kwiatkowski F, Durando X, van Praagh-Doreau I, Chevrier R.

Support Care Cancer. 2019 Nov 22. doi: 10.1007/s00520-019-05144-x. [Epub ahead of print]

PMID:
31758323

Supplemental Content

Loading ...
Support Center